MRTX logo

Mirati Therapeutics (MRTX) CAPEX

Annual CAPEX

$4.85 M
-$4.94 M-50.47%

December 31, 2022

Summary

Performance

1-Year Change

-50.47%

3-Year Change

+212.56%

5-Year Change

+5888.89%

15-Year Change

+5888.89%

MRTX CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$9.79 M
MRTX annual capital expenditures is currently -50.47% below its historical high of $9.79 million

3-Year Low

$4.85 M
MRTX annual capital expenditures is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
MRTX previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
MRTX next annual earnings announcement has not yet been scheduled

OtherMRTXcash flowmetrics:

Annual FCF

-$575.42 M
MRTX annual free cash flow is -$575.42 million

Annual CFO

-$570.57 M
MRTX annual cash flow from operations is -$570.57 million

Annual CFI

$225.80 M
MRTX annual cash flow from investing activities is $225.80 million

Annual CFF

$166.94 M
MRTX annual cash flow from financing activities is $166.94 million

Quarterly CAPEX

$36.00 K
-$686.00 K-95.01%

September 30, 2023

Summary

Performance

3-Month Change

-95.01%

1-Year Change

-97.1%

3-Year Change

-97.49%

5-Year Change

0%

MRTX Quarterly CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$4.03 M
MRTX quarterly capital expenditures is currently -99.11% below its historical high of $4.03 million

3-Year Low

$36.00 K
MRTX quarterly capital expenditures is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
MRTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
MRTX next earnings announcement has not yet been scheduled

OtherMRTXcash flowmetrics:

Quarterly FCF

-$143.75 M
MRTX quarterly free cash flow is -$143.75 million

Quarterly CFO

-$143.71 M
MRTX quarterly cash flow from operations is -$143.71 million

Quarterly CFI

-$62.19 M
MRTX quarterly cash flow from investing activities is -$62.19 million

Quarterly CFF

$334.70 M
MRTX quarterly cash flow from financing activities is $334.70 million

TTM CAPEX

$1.84 M
-$1.20 M-39.59%

September 30, 2023

Summary

Performance

3-Month Change

-39.59%

1-Year Change

-72.54%

3-Year Change

-56.19%

5-Year Change

+18.36%

MRTX TTM CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$9.83 M
MRTX TTM capital expenditures is currently -81.31% below its historical high of $9.83 million

3-Year Low

$1.84 M
MRTX TTM capital expenditures is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
MRTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
MRTX next earnings announcement has not yet been scheduled

OtherMRTXcash flowmetrics:

TTM FCF

-$595.93 M
MRTX TTM free cash flow is -$595.93 million

TTM CFO

-$594.10 M
MRTX TTM cash flow from operations is -$594.10 million

TTM CFI

$207.79 M
MRTX TTM cash flow from investing activities is $207.79 million

TTM CFF

$346.19 M
MRTX TTM cash flow from financing activities is $346.19 million

MRTX CAPEX Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-50.5%-97.1%-72.5%
3 y3 years+212.6%-97.5%-56.2%
5 y5 years+5888.9%0.0%+18.4%

MRTX CAPEX Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-50.5%at low-98.6%at low-81.3%at low
5 y5-year-50.5%-68.0%-99.1%at low-81.3%-15.5%
alltimeall time-50.5%-99.9%-99.1%-341.9%-81.3%-103.9%

Mirati Therapeutics CAPEX History

DateAnnualQuarterlyTTM
Sep 2023
-
$36.00 K(-95.0%)
$1.84 M(-39.6%)
Jun 2023
-
$722.00 K(+168.4%)
$3.04 M(-23.6%)
Mar 2023
-
$269.00 K(-66.8%)
$3.98 M(-18.0%)
Dec 2022
$4.85 M(-50.5%)
$810.00 K(-34.7%)
$4.85 M(-27.5%)
Sep 2022
-
$1.24 M(-25.3%)
$6.69 M(-10.3%)
Jun 2022
-
$1.66 M(+45.7%)
$7.46 M(-24.1%)
Mar 2022
-
$1.14 M(-57.0%)
$9.83 M(+0.3%)
Dec 2021
$9.79 M(+124.3%)
$2.65 M(+31.9%)
$9.79 M(+13.2%)
Sep 2021
-
$2.01 M(-50.1%)
$8.65 M(+7.1%)
Jun 2021
-
$4.03 M(+264.0%)
$8.08 M(+53.9%)
Mar 2021
-
$1.11 M(-26.5%)
$5.25 M(+20.2%)
Dec 2020
$4.37 M(+181.4%)
$1.51 M(+4.9%)
$4.37 M(+4.1%)
Sep 2020
-
$1.44 M(+19.6%)
$4.19 M(+44.2%)
Jun 2020
-
$1.20 M(+436.2%)
$2.91 M(+63.7%)
Mar 2020
-
$224.00 K(-83.2%)
$1.78 M(+14.4%)
Dec 2019
$1.55 M(+1172.1%)
$1.33 M(+782.1%)
$1.55 M(+407.2%)
Sep 2019
-
$151.00 K(+118.8%)
$306.00 K(+60.2%)
Jun 2019
-
$69.00 K(-19.8%)
$191.00 K(+56.6%)
Dec 2018
$122.00 K(+50.6%)
$86.00 K(+138.9%)
$122.00 K(+229.7%)
Sep 2018
-
$36.00 K(+3500.0%)
$37.00 K(-54.3%)
Dec 2017
$81.00 K(-58.7%)
$1000.00(>+9900.0%)
$81.00 K(-62.0%)
Sep 2017
-
$0.00(-100.0%)
$213.00 K(-7.8%)
Jun 2017
-
$80.00 K(-39.8%)
$231.00 K(+17.9%)
Dec 2016
$196.00 K(-40.4%)
$133.00 K(+638.9%)
$196.00 K(+104.2%)
Sep 2016
-
$18.00 K(>+9900.0%)
$96.00 K(+24.7%)
Jun 2016
-
$0.00(-100.0%)
$77.00 K(-78.4%)
Mar 2016
-
$45.00 K(+36.4%)
$356.00 K(+8.2%)
Dec 2015
$329.00 K(-14.8%)
$33.00 K(-3400.0%)
$329.00 K(-9.1%)
Sep 2015
-
-$1000.00(-100.4%)
$362.00 K(-13.6%)
Jun 2015
-
$279.00 K(+1450.0%)
$419.00 K(+4.2%)
Mar 2015
-
$18.00 K(-72.7%)
$402.00 K(+4.1%)
Dec 2014
$386.00 K(+89.2%)
$66.00 K(+17.9%)
$386.00 K(+17.7%)
Sep 2014
-
$56.00 K(-78.6%)
$328.00 K(+5.1%)
Jun 2014
-
$262.00 K(>+9900.0%)
$312.00 K(+169.0%)
Mar 2014
-
$2000.00(-75.0%)
$116.00 K(-43.1%)
DateAnnualQuarterlyTTM
Dec 2013
$204.00 K(-11.3%)
$8000.00(-80.0%)
$204.00 K(-42.9%)
Sep 2013
-
$40.00 K(-39.4%)
$357.00 K(+6.6%)
Jun 2013
-
$66.00 K(-26.7%)
$335.00 K(+5.3%)
Mar 2013
-
$90.00 K(-44.1%)
$318.00 K(+38.3%)
Dec 2012
$230.00 K(+115.4%)
$161.00 K(+794.4%)
$230.00 K(+133.0%)
Sep 2012
-
$18.00 K(-63.3%)
$98.70 K(-36.2%)
Jun 2012
-
$49.00 K(+2350.0%)
$154.70 K(+42.2%)
Mar 2012
-
$2000.00(-93.3%)
$108.80 K(+1.9%)
Dec 2011
$106.80 K(+1425.7%)
$29.70 K(-59.9%)
$106.80 K(+40.0%)
Sep 2011
-
$74.00 K(+2287.1%)
$76.30 K(+1339.6%)
Jun 2011
-
$3100.00(-487.5%)
$5300.00(-23.2%)
Dec 2010
$7000.00(-85.0%)
-$800.00(-126.7%)
$6900.00(-82.5%)
Sep 2010
-
$3000.00(-1600.0%)
$39.50 K(-9.6%)
Jun 2010
-
-$200.00(-104.1%)
$43.70 K(-15.5%)
Mar 2010
-
$4900.00(-84.6%)
$51.70 K(+10.5%)
Dec 2009
$46.80 K(-78.3%)
$31.80 K(+341.7%)
$46.80 K(-164.9%)
Sep 2009
-
$7200.00(-7.7%)
-$72.10 K(-214.8%)
Jun 2009
-
$7800.00(-109.0%)
$62.80 K(-70.9%)
Dec 2008
$216.10 K(-85.4%)
-$87.10 K(-161.3%)
$216.10 K(-78.9%)
Sep 2008
-
$142.10 K(+166.6%)
$1.03 M(-6.9%)
Jun 2008
-
$53.30 K(-50.6%)
$1.10 M(-17.3%)
Mar 2008
-
$107.80 K(-85.1%)
$1.33 M(-10.2%)
Dec 2007
$1.48 M(+55.0%)
$722.90 K(+232.1%)
$1.48 M(+40.6%)
Sep 2007
-
$217.70 K(-23.5%)
$1.06 M(-2.9%)
Jun 2007
-
$284.50 K(+9.7%)
$1.09 M(+3.0%)
Mar 2007
-
$259.30 K(-11.8%)
$1.05 M(+10.1%)
Dec 2006
$957.40 K(-32.2%)
$293.90 K(+18.2%)
$957.50 K(+42.1%)
Sep 2006
-
$248.70 K(-1.5%)
$673.60 K(+17.9%)
Jun 2006
-
$252.40 K(+55.3%)
$571.10 K(-54.5%)
Mar 2006
-
$162.50 K(+1525.0%)
$1.26 M(-10.9%)
Dec 2005
$1.41 M(+84.3%)
$10.00 K(-93.2%)
$1.41 M(+0.7%)
Sep 2005
-
$146.20 K(-84.4%)
$1.40 M(+11.7%)
Jun 2005
-
$937.80 K(+195.8%)
$1.25 M(+295.8%)
Mar 2005
-
$317.00 K
$317.00 K
Dec 2004
$765.80 K(-18.0%)
-
-
Dec 2003
$934.10 K
-
-

FAQ

  • What is Mirati Therapeutics annual capital expenditures?
  • What is the all time high annual CAPEX for Mirati Therapeutics?
  • What is Mirati Therapeutics annual CAPEX year-on-year change?
  • What is Mirati Therapeutics quarterly capital expenditures?
  • What is the all time high quarterly CAPEX for Mirati Therapeutics?
  • What is Mirati Therapeutics quarterly CAPEX year-on-year change?
  • What is Mirati Therapeutics TTM capital expenditures?
  • What is the all time high TTM CAPEX for Mirati Therapeutics?
  • What is Mirati Therapeutics TTM CAPEX year-on-year change?

What is Mirati Therapeutics annual capital expenditures?

The current annual CAPEX of MRTX is $4.85 M

What is the all time high annual CAPEX for Mirati Therapeutics?

Mirati Therapeutics all-time high annual capital expenditures is $9.79 M

What is Mirati Therapeutics annual CAPEX year-on-year change?

Over the past year, MRTX annual capital expenditures has changed by -$4.94 M (-50.47%)

What is Mirati Therapeutics quarterly capital expenditures?

The current quarterly CAPEX of MRTX is $36.00 K

What is the all time high quarterly CAPEX for Mirati Therapeutics?

Mirati Therapeutics all-time high quarterly capital expenditures is $4.03 M

What is Mirati Therapeutics quarterly CAPEX year-on-year change?

Over the past year, MRTX quarterly capital expenditures has changed by -$1.20 M (-97.10%)

What is Mirati Therapeutics TTM capital expenditures?

The current TTM CAPEX of MRTX is $1.84 M

What is the all time high TTM CAPEX for Mirati Therapeutics?

Mirati Therapeutics all-time high TTM capital expenditures is $9.83 M

What is Mirati Therapeutics TTM CAPEX year-on-year change?

Over the past year, MRTX TTM capital expenditures has changed by -$4.85 M (-72.54%)